Kanki P - Search Results

1

Cellular immunity to human immunodeficiency virus type 1 (HIV-1) clades: relevance to HIV-1 vaccine trials in Uganda.

Cao H, Mani I, Vincent R, Mugerwa R, Mugyenyi P, Kanki P, Ellner J, Walker BD. Cao H, et al. Among authors: kanki p. J Infect Dis. 2000 Nov;182(5):1350-6. doi: 10.1086/315868. Epub 2000 Oct 9. J Infect Dis. 2000. PMID: 11023458 Clinical Trial.

2

Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine development.

Cao H, Kanki P, Sankalé JL, Dieng-Sarr A, Mazzara GP, Kalams SA, Korber B, Mboup S, Walker BD. Cao H, et al. Among authors: kanki p. J Virol. 1997 Nov;71(11):8615-23. doi: 10.1128/JVI.71.11.8615-8623.1997. J Virol. 1997. PMID: 9343219 Free PMC article.

3

In vitro correlates of HIV-2-mediated HIV-1 protection.

Kokkotou EG, Sankale JL, Mani I, Gueye-Ndiaye A, Schwartz D, Essex ME, Mboup S, Kanki PJ. Kokkotou EG, et al. Among authors: kanki pj. Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6797-802. doi: 10.1073/pnas.97.12.6797. Proc Natl Acad Sci U S A. 2000. PMID: 10841574 Free PMC article.

4

Intrapatient diversity and its correlation with viral setpoint in human immunodeficiency virus type 1 CRF02_A/G-IbNG infection.

Mani I, Gilbert P, Sankalé JL, Eisen G, Mboup S, Kanki PJ. Mani I, et al. Among authors: kanki pj. J Virol. 2002 Nov;76(21):10745-55. doi: 10.1128/jvi.76.21.10745-10755.2002. J Virol. 2002. PMID: 12368317 Free PMC article.

5

Robust HIV type 2 cellular immune response measured by a modified anthrax toxin-based enzyme-linked immunospot assay.

Sarr AD, Lu Y, Sankalé JL, Eisen G, Popper S, Mboup S, Kanki PJ, Cao H. Sarr AD, et al. Among authors: kanki pj. AIDS Res Hum Retroviruses. 2001 Sep 1;17(13):1257-64. doi: 10.1089/088922201750461311. AIDS Res Hum Retroviruses. 2001. PMID: 11559425

6

Resistance to human immunodeficiency virus type 1 in vitro as a surrogate of vaccine-induced protective immunity.

Castillo RC, Arango-Jaramillo S, John R, Weinhold K, Kanki P, Carruth L, Schwartz DH. Castillo RC, et al. Among authors: kanki p. J Infect Dis. 2000 Mar;181(3):897-903. doi: 10.1086/315300. J Infect Dis. 2000. PMID: 10720510

7

Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2.

Popper SJ, Sarr AD, Travers KU, Guèye-Ndiaye A, Mboup S, Essex ME, Kanki PJ. Popper SJ, et al. Among authors: kanki pj. J Infect Dis. 1999 Oct;180(4):1116-21. doi: 10.1086/315010. J Infect Dis. 1999. PMID: 10479138

8

Plasma RNA viral load as measured by the branched DNA and nucleic acid sequence-based amplification assays of HIV-1 subtypes A and D in Uganda.

Mani I, Cao H, Hom D, Johnson JL, Mugerwa RD, Travers KU, Caliendo AM, Walker BD, Kanki PJ. Mani I, et al. Among authors: kanki pj. J Acquir Immune Defic Syndr. 1999 Oct 1;22(2):208-9. doi: 10.1097/00126334-199910010-00016. J Acquir Immune Defic Syndr. 1999. PMID: 10843537 No abstract available.

9

Human immunodeficiency virus type 1 subtypes differ in disease progression.

Kanki PJ, Hamel DJ, Sankalé JL, Hsieh Cc, Thior I, Barin F, Woodcock SA, Guèye-Ndiaye A, Zhang E, Montano M, Siby T, Marlink R, NDoye I, Essex ME, MBoup S. Kanki PJ, et al. J Infect Dis. 1999 Jan;179(1):68-73. doi: 10.1086/314557. J Infect Dis. 1999. PMID: 9841824

10

High levels of tumor necrosis factor-alpha and interleukin-1beta in bacterial vaginosis may increase susceptibility to human immunodeficiency virus.

Sturm-Ramirez K, Gaye-Diallo A, Eisen G, Mboup S, Kanki PJ. Sturm-Ramirez K, et al. Among authors: kanki pj. J Infect Dis. 2000 Aug;182(2):467-73. doi: 10.1086/315713. Epub 2000 Jul 18. J Infect Dis. 2000. PMID: 10915077

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

237 results

Search Page

Filters